^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER negative

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    12h
    NEOSHED: Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=186, Not yet recruiting, Federico II University
    New trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    ER negative
    1d
    Risk stratification assessment of brain metastasis in newly diagnosed non-stage IV breast cancer patients with HER-2-low expression following systemic therapy (PubMed, Zhonghua Zhong Liu Za Zhi)
    The incidence of brain metastases in each group were 0 (0/3), 33.33% (39/117), 74.55% (82/110) and 100.00% (17/17), respectively. The risk stratification of brain metastasis based on clinicopathological characteristics and levels of related tumor markers are helpful to predict the risk of brain metastasis in non-stage Ⅳ breast cancer patients with HER-2 low expression after systematic treatment, so as to accurately identify patients with high recurrence risk and formulate targeted follow-up strategies for them.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 expression • HER-2 underexpression • ER negative
    3d
    Enzymatically derived chitooligosaccharides exhibit enhanced therapeutic efficacy against estrogen receptor-positive and triple-negative breast cancer cells. (PubMed, Int J Biol Macromol)
    In summary, these findings suggest that E-NACOS exert relevant anti-migratory and pro-apoptotic effects in breast cancer cell models, potentially through oxidative stress associated mechanisms. Although further mechanistic insights and in vivo validation are required, A. faecalis-derived E-NACOS represent a promising bioactive preparation worthy of continued exploration for prospective applications in breast cancer management.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    7d
    First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC ) (clinicaltrials.gov)
    P1, N=60, Recruiting, Immunomic Therapeutics, Inc.
    New P1 trial • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative • BRCA mutation
    |
    Keytruda (pembrolizumab)
    7d
    HER2-low status in breast cancer: clinicopathological factors and prognostic value. (PubMed, Arch Med Sci)
    HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 overexpression • ER negative • HER-2 overexpression + HR positive • HER-2 positive + HER-2 overexpression
    9d
    A Case Report: A Rare Casr Mutation Associated with HER2-Positive Breast Cancer. (PubMed, Exp Oncol)
    The patient underwent neoadjuvant chemothera- py, right-sided mastectomy, and trastuzumab therapy, achieving complete pathological regression (pCR) with no recur- rence after ten months of follow-up. Although the CASR p.Glu755Asp variant's pathogenic role is unproven, emerging evidence links CASR overexpression with hER2-positive breast cancers, promoting tumor progression via calcium- dependent signaling pathways (PI3K/AKt, MAPK). This case highlights the potential role of CASR as a low-penetrance susceptibility gene in breast cancer and supports further functional and genomic studies to clarify its clinical impact.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • CASR (Calcium Sensing Receptor)
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • HER-2 mutation • PALB2 mutation • ER negative • CHEK2 mutation • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab)
    13d
    ETCTN 10302: Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • ER negative
    |
    paclitaxel • Xofigo (radium Ra-223 dichloride)
    13d
    Expression of visfatin, lipocalin-2, adiponectin, and chemerin in breast cancer and their association with clinicopathological parameters. (PubMed, Arch Med Sci Atheroscler Dis)
    These findings point to visfatin and adiponectin as potential indicators of aggressive breast cancer phenotypes, while lipocalin-2 may follow a different biological trajectory. Larger, prospective studies are warranted to confirm these associations and clarify underlying mechanisms.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • LCN2 (Lipocalin-2) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    ER negative
    14d
    ABC-R: Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM. (clinicaltrials.gov)
    P2, N=58, Recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • HER-2 negative + HR negative
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • AiRuiLi (adebrelimab)
    16d
    Dysregulated KIF2A correlates with p53 expression pattern in breast cancer. (PubMed, Mol Cell Biochem)
    This study revealed the expression interplay and clinical significance of KIF2A and p53 in breast cancer. The identified association between KIF2A and p53 may provide insights for future research on their roles in breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER negative • EGFR positive
    18d
    The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status. (PubMed, NPJ Breast Cancer)
    Conversely, in ER-positive tumors, apocrine morphology was associated with increased proliferation, enhanced immune-related signaling, and greater genomic instability. In conclusion, apocrine morphology represents an ER-dependent biological state with distinct prognostic and molecular implications.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    18d
    STARTER: Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • ER negative
    |
    capecitabine • Jiataile (sacituzumab tirumotecan)